A triple combination of brachytherapy, external beam radiotherapy (EBRT), and hormonal therapy is associated with favorable outcomes in men with high-grade prostate cancer and should be considered a viable treatment option in these patients, a study showed.

The study, conducted by Richard G. Stock, MD, and colleagues at Mount Sinai School of Medicine in New York City, included 181 prostate cancer patients with Gleason scores of 8-10 who received treatment with palladium 103 implants (prescription dose 100 Gy), 45 Gy of EBRT, and nine months of hormone therapy.

The eight-year actuarial freedom from biochemical failure, freedom from distant metastases, prostate cancer-specific survival, and overall survival rates were 73%, 80%, 87%, and 79%, respectively, investigators reported in BJU International (2009; published online ahead of print).

Continue Reading